Comparative Pharmacology
Head-to-head clinical analysis: GALLIUM GA 68 GOZETOTIDE versus SODIUM CHROMATE CR 51.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GALLIUM GA 68 GOZETOTIDE versus SODIUM CHROMATE CR 51.
GALLIUM GA 68 GOZETOTIDE vs SODIUM CHROMATE CR 51
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gallium Ga 68 gozetotide is a radioactive diagnostic agent that binds to prostate-specific membrane antigen (PSMA), a transmembrane protein overexpressed on prostate cancer cells. After binding, the gallium-68 isotope emits positrons for PET imaging.
Radiolabeled sodium chromate (51Cr) binds to red blood cells, tagging them for survival studies. 51Cr emits gamma radiation, allowing detection and quantification of RBC mass and survival via scintillation counting or imaging.
148-222 MBq (4-6 mCi) intravenously as a single dose for PET imaging.
Intravenous injection, 5-30 microcuries (0.185-1.11 MBq) as a single dose.
None Documented
None Documented
Terminal elimination half-life: 1.5 hours (range 1.2–1.8 hours) based on decay of Gallium-68 and renal clearance. Clinically, this allows imaging up to 2–3 hours post-injection.
The biological half-life is approximately 27–30 days. Clinically, gradual clearance from blood and tissues occurs over weeks to months.
Renal excretion: 100% of administered dose eliminated unchanged in urine within 24 hours. No biliary or fecal elimination significant.
Primarily renal. Approximately 90% of absorbed dose is excreted in urine within 48 hours. Fecal excretion accounts for less than 5%.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical